Biomedical subjects
L Corea
Publications and source records attributed to L Corea.
Leucocyte rheology in controlled coronary ischaemia.
Since no studies have been carried out on the exact origin of the alterations in white blood cell rheology during the early stages of controlled ischaemia in coronary arterial disease, a model was set up using a cycle ergometer test (with a 25 watts increase every 2 minutes). Blood samples were taken (before and after exercise and again 8 minutes later at recovery) from 18 patients with stable angina pectoris and a group of 22 matched controls. The filterability (through 5 micrometer diameter pore filters) of the polymorphonuclear leucocyte sub-population (separated by density gradient), the monocyte and lymphocyte sub-fractions (separated by adhesion to Petri dishes) as well as leucocyte activation (observed under a light microscope) were monitored. Our results showed that the total leucocyte count in patients and controls rose after exercise and was accompanied by a differential shift from the polymorphonuclear to the lymphocyte cells. The polymorphonuclear filterability rate increased significantly in patients when compared to their basal values at rest, and to the controls after exercise (+ 19.58%; P less than 0.002 vs basal values at rest; + 18.72%; P less than 0.002 vs controls). This increase persisted throughout the recovery period (+ 19.86%; P less than 0.002 vs basal values; and + 23.52% P less than 0.001 vs controls), indicating that a reduced polymorphonuclear leucocyte filterability can be associated with the first signs of ischaemia.
[Multicenter clinical study of the antihypertensive activity of lisinopril].
One-hundred patients suffering from slight-moderate hypertension (53 m, 47 f, aged between 18 and 78, average 49.08) have been studied in order to assess the effectiveness and tolerance of lisinopril ("Zestril", ICI-Pharma), a new ACE inhibitor in a single daily administration at doses of between 10 and 80 mg in relation to pressure values. Monotherapy with Lisinopril proved effective in 84 patients (88.4%), in 74 of whom (7.9%) pressure values were returned to normal. 11 patients (11.6%) did not respond to treatment. In most cases, the result was obtained with a dose of 20 mg in a single administration (32.6%). The incidence of side-effects was limited and in no case required the withdrawal of the drug.
[Secondary prevention in the post-infarction period].
Explore the source record for details and available documents.
[Doppler echocardiography in atrial myxoma].
Two-dimensional echocardiography is the technique of choice for the diagnosis of atrial myxoma. In fact the Echo study allows the recognition of the presence of the tumor, and can show its dimensions, shape, implantation site and motility. However, it is not clear the role of Doppler echocardiography in the evaluation of atrial myxoma. This technique could be useful to recognize patients with more severe obstruction to atrioventricular flow due to large tumors. In 4 patients with large atrial myxomas (3 left and 1 right atrial myxoma) Doppler analysis of atrioventricular flow showed an apparent correlation between variation of trans-mitral or trans-tricuspid diastolic flow and symptoms (syncopal attacks). Only patients with an obstruction to atrioventricular flow and severely restricted calculated mitral or tricuspid orifice had syncopal attacks, at variance with patients without flow obstruction. Further studies on larger population will verify this apparent relation between atrioventricular flow obstruction and clinical symptoms in patients with large atrial myxoma.
Echocardiography and septal thickness.
Explore the source record for details and available documents.
A multicenter trial of low dose captopril administered twice daily in patients with essential hypertension unresponsive to beta blocker-diuretic treatment.
Two hundred and one patients with essential hypertension, whose supine diastolic blood pressure (SDBP) was greater than or equal to 95 mmHg following 2 weeks of treatment with the optimal dose of a beta blocker-diuretic combination (Phase 1), were randomly assigned to the addition of either 25 or 50 mg captopril BID for 6 weeks (Phase 2). At the end of Phase 2, the dose of captopril was doubled in the patients not normalized (SDBP greater than or equal to 95 mmHg) and maintained in the others (SDBP less than 95) for an additional 4 weeks (Phase 3). At the end of Phase 3, the beta blocker was withdrawn in the normalized (SDBP less than 95 mmHg) patients, and captopril plus diuretic was given for 4 weeks (Phase 4). The addition of captopril at either dose level led to a significant fall (p less than 0.01) in standing and supine diastolic and systolic blood pressure after the first 2 weeks of treatment. There was no significant difference in response between the two dose levels of captopril. At the end of Phase 2, 59.4% and 55.8% of patients, respectively, assigned to 25 and 50 mg captopril BID, were normalized. Doubling the dose of captopril (Phase 3) led to approximately an additional 30% of patients being normalized. At the end of Phase 4 (captopril plus diuretic) the SDBP was still less than 95 mmHg in 63% of patients, whereas it was increased in the others. Side effects were noted in 10 patients (5%). The incidence was similar in each treatment group, and a total of four patients (2%) were withdrawn due to side effects.
[Left ventricular hypertrophy in systemic arterial hypertension. 1987].
Explore the source record for details and available documents.
High prevalence of septal thickness overestimation in hypertensive subjects and controls.
The aim of our study was to assess the frequency of important problems in the ultrasonic estimate of septal thickness as a consequence of multiple endocardial lines inside the septum in echocardiographic tracings of otherwise good technical quality. We performed an echocardiographic study in a population composed of 311 subjects (131 essential hypertensive subjects and 180 normotensive healthy controls) by using M-mode echocardiography under two-dimensional control, according to the recommendations of the American Society of Echocardiography. We observed the presence of one or more continuous lines inside the septum, each of them simulating an endocardial border and thus producing the appearance of two or more superimposed septal thicknesses differing by 2 mm or more in greater than 50% of the subjects (54% normotensive and 56% hypertensive). Furthermore, within the group of subjects with multiple septal lines, we found the disappearance of at least one of the farthest linear echoes, with resulting septal thinning of almost 2 mm in 58% of the normotensive and 61% of the hypertensive subjects. These findings suggest the need for caution when interpreting echocardiographic measurements of left ventricular septal thickness. We suggest that in the presence of multiple lines inside the septum, the echocardiographic examination should be continued up to the appearance of the thinnest septal image, possibly devoid of multiple lines inside the septum.
Antihypertensive efficacy and tolerability of captopril in the elderly: comparison with hydrochlorothiazide and placebo in a multicentre, double-blind study.
In this study we compared the antihypertensive efficacy and tolerability of captopril at 25 mg twice daily, hydrochlorothiazide (HCTZ), 12.5 mg twice daily and placebo in a multicentre, double-blind, randomized study that included 152 essential hypertensive patients (77 males, 75 females, 87 WHO stage I, 65 WHO stage II, aged 69 +/- 4 years, mean +/- s.d.). Supine and standing blood pressure were similarly reduced by captopril and HCTZ (P less than 0.01 for both compared with placebo). The heart rate did not change. Captopril (25-30 mg twice daily) and HCTZ (12.5 mg twice daily), alone or in combination, maintained their antihypertensive effect during a 24-week single-blind follow-up study. During the follow-up, diastolic blood pressure remained less than 100 mmHg in seven essential hypertensives on placebo, in 45 on captopril and in 25 on HCTZ. Side effects were observed in seven essential hypertensives during placebo (treatment withdrawn in two), in eight during HCTZ and in three during captopril. Serum potassium was reduced (P less than 0.05) and uric acid was increased (P less than 0.01) only during HCTZ. We conclude that captopril and HCTZ have similar antihypertensive efficacy in the elderly; however, captopril appears to be better tolerated.
[Diuretics in the treatment of congestive heart failure].
Explore the source record for details and available documents.
Similarities and differences in the antihypertensive effect of two calcium antagonist drugs, verapamil and nifedipine.
The short- and long-term effects of two calcium channel blocking drugs, verapamil and nifedipine, on blood pressure, heart rate, plasma catecholamines, plasma renin activity, plasma volume and cardiac performance (echocardiography) were studied in essential hypertensive patients and in normal subjects. Verapamil, 160 mg orally, reduced blood pressure within 60 minutes in 22 hypertensive patients, but not in 12 normotensive subjects. Nifedipine, 10 mg sublingually, reduced blood pressure within 15 minutes in 19 hypertensive patients, but not in 7 normotensive subjects. Plasma noradrenaline was significantly increased both in normal subjects and in hypertensive patients only after nifedipine was administered. Verapamil (80 mg three times a day) first, and nifedipine (10 mg three times a day) thereafter, or vice versa, were given to 12 hospitalized hypertensive patients on a fixed sodium and potassium intake; the drugs produced similar blood pressure reductions, but heart rate and plasma catecholamines were increased only after nifedipine (p less than 0.05). Neither drug affected plasma volume, aldosterone or plasma renin activity. Long-term ambulatory treatment with verapamil (80 or 160 mg three times a day for 2 to 4 months) or nifedipine (10 mg three times a day for 2 months) produced changes in all variables that were similar to those observed in the hospital (controlled) study. Shortening fraction was significantly increased after nifedipine (p less than 0.05) but no change was observed after verapamil. In conclusion, blood pressure is effectively reduced by both verapamil and nifedipine; an appreciable adrenergic stimulation may be caused by nifedipine, but usually not by verapamil, and fluid retention, renin release or myocardial depression is not observed during verapamil or nifedipine treatment.
Comparative effects on blood pressure of different calcium-blocking agents.
Explore the source record for details and available documents.
[Clinical recognition of ventricular hypertrophy: echocardiography].
Explore the source record for details and available documents.
[Effects of enalapril on the mass and function of the left ventricle in hypertensive subjects].
Explore the source record for details and available documents.
Effect of captopril on left ventricular mass and function in hypertensive patients and in the rat.
Twenty-seven mild to moderate essential hypertensive patients were treated with captopril alone or combined with hydrochlorothiazide and left ventricular echocardiographic changes were evaluated after 1, 3 and 6 months. The left ventricular mass decreased slightly after 3 months, together with mean wall stress and total peripheral resistance, while the cardiac performance, as measured by fractional shortening and cardiac output, was unaffected. A high degree of individual variability was observed, and only 9 out of 20 patients examined after 3 months had a consistent reduction in left ventricular mass. The effect of captopril on the isomyosin composition was also evaluated in 4 normotensive rats after 12 weeks of drug administration. No interference with the physiological pattern was observed and no modifications of the biochemical and structural properties of the myocardium were detected.
Age and responses to isometric exercise in hypertension: possible predictors of the antihypertensive effect of diuretics and beta-blockers.
In a multicenter, randomized, double-blind study, 108 hypertensive patients were treated with either chlorthalidone 25 mg or slow-release metoprolol 200 mg both given once daily over 4 weeks. Blood pressure and heart rate at rest and at the peak of an isometric exercise test (30% of maximal voluntary contraction for 3 min) were recorded at random and at the end of the study. Both treatments induced a significant (p less than 0.01) blood pressure reduction at rest and at the peak exercise, 50.0% of patients on chlorthalidone and 59.2% on metoprolol, respectively, having a lying diastolic blood pressure less than 95 mmHg. A weak but significant (p less than 0.001) positive correlation was found between age and change in systolic and diastolic blood pressure after chlorthalidone. Such a relationship was absent in the metoprolol group, where a significant (p less than 0.01) positive correlation was found between diastolic pressure rise from rest to the peak exercise at randomization, and the reduction in resting diastolic pressure at the end of the study. Treatments were well tolerated, only a decrease (p less than 0.05) in serum potassium (from 4.4 to 4.0 mEq/l) in the chlorthalidone group was observed. Results suggest that age may influence the antihypertensive response to chlorthalidone, while diastolic pressure rise in isometric exercise may predict the degree of pressure response to sustained beta-adrenergic blockade with metoprolol.
Plasma norepinephrine and left ventricular hypertrophy in systemic hypertension.
The relations between some pressure and humoral factors, and some echocardiographic indexes of left ventricular (LV) hypertrophy were studied in 64 patients with essential hypertension. Fifty-seven percent of these patients showed echocardiographic evidence of LV hypertrophy (LV mass greater than 215 g). Multivariate stepwise regression analysis showed that only mean blood pressure (BP) and circulating norepinephrine (NE) levels were significantly related to LV mass index in the group of patients with LV hypertrophy. However, mean BP was the only factor related to LV mass index in the subgroup of patients with LV hypertrophy and plasma NE within the normal laboratory range, whereas NE was the sole factor related to LV mass index in the subgroup with LV hypertrophy and abnormally elevated NE levels (greater than mean + 2 standard deviations of the normal laboratory range). Correlation of LV mass index vs NE was -0.35 (not significant) in the former group of patients and 0.89 (p less than 0.01) in the latter group. NE showed no relation with the echocardiographic variables in the hypertensive patients without LV hypertrophy; in this group, diastolic BP was the only factor related to LV mass index. Circulating NE levels were slightly higher in patients with LV hypertrophy (213 +/- 68 ng/liter) than in those without LV hypertrophy (187 +/- 46 ng/liter), but differences were not significant when adjusting NE for age. Plasma renin activity was not dissimilar in the absence or presence of hypertrophy. In conclusion, our findings suggest that NE might be associated with pressure factors in regulating LV hypertrophy development only in a subgroup of hypertensive patients characterized by echocardiographic LV hypertrophy and abnormally elevated circulating NE levels.